June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Outer Retinal Tubulations in the Comparison of AMD Treatments Trials (CATT)
Author Affiliations & Notes
  • Joo Yong Lee
    Duke Eye Center, Durham, NC
    Ophthalmology, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea
  • Francisco Folgar
    Duke Eye Center, Durham, NC
  • Cynthia Toth
    Duke Eye Center, Durham, NC
  • Glenn Jaffe
    Duke Eye Center, Durham, NC
  • Footnotes
    Commercial Relationships Joo Yong Lee, None; Francisco Folgar, None; Cynthia Toth, Genentech (F), Bioptigen (F), Physical Sciences Inc. (F), Unlicensed (P); Glenn Jaffe, Heidelberg Engineering (C), Regeneron Pharmaceuticals (F), Neurotech USA (C), Abbott (C), Psivida (F), Pfizer (C), Bayer (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 6268. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joo Yong Lee, Francisco Folgar, Cynthia Toth, Glenn Jaffe, Comparison of AMD Treatments Trials (CATT); Outer Retinal Tubulations in the Comparison of AMD Treatments Trials (CATT). Invest. Ophthalmol. Vis. Sci. 2013;54(15):6268.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To determine the prevalence of outer retinal tubulation (ORT) seen on spectral domain optical coherence tomography (SD-OCT) in eyes with neovascular age-related macular degeneration (ARMD) following anti-VEGF therapy, and to correlate ORTs with intra-retinal fluid (IRF), subretinal fluid (SRF), and retinal, subretinal fluid, and subretinal tissue complex (SRTC) thickness.

Methods: Participants in CATT were randomly assigned to ranibizumab (0.5mg) or bevacizumab (1.25mg) treatment and to a monthly or PRN injection dosing regimen. A subset, 81 eyes had SD-OCT scans beginning at Week 56. The original CATT grading protocol did not distinguish ORTs from cysts in eyes with IRF, or ORTs from small SRF pockets in eyes with SRF. Accordingly the subset of 58 eyes at Week 56 with IRF and SRF was selected for ORT analysis. Horizontal SD-OCT B-scan images as determined by the CATT OCT Reading Center, were evaluated. Cirrus 512x128 or Spectralis 20°x20° volume cube scan protocols were used to acquire SD-OCT images. 2 independent readers graded scans, and a senior reader arbitrated discrepant grades. The prevalence of ORTs, identified as a tubular structure seen on at least 3 consecutive Cirrus B scans or 2 consecutive Spectralis B scans was determined. Retinal, SRF, and SRTC foveal center thicknesses were compared in eyes with and without ORTs.

Results: Of the 81 eyes, 7 (8.4%) had ORTs. Among the 38 eyes with IRF, 7 (18.4%) also had ORTs and among 20 eyes with only SRF none had ORTs. Among eyes with IRF and ORT, the mean foveal center retinal, SRF, and SRTC thicknesses were 116.1±40.6, 4.7±12.5 µm, and 96.4±68.3, respectively. The corresponding mean thicknesses in eyes without ORTs were 180.6±92.5µm, 4.8±18.6µm, and 146.9±126.8µm respectively. The difference in mean retinal thickness (64.5 µm) in eyes with and without ORTs was statistically significantly (p=0.009).

Conclusions: ORTs were seen relatively commonly in eyes with neovascular AMD and residual IRF following anti-VEGF therapy. Eyes with ORTs had thinner retinas than those without ORTs. These findings suggest that ORTs are related to degenerative changes in neural tissue in eyes with residual IRF.

Keywords: 412 age-related macular degeneration • 550 imaging/image analysis: clinical  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.